Literature DB >> 30940659

Antagonism between HTRA3 and TGFβ1 Contributes to Metastasis in Non-Small Cell Lung Cancer.

Jingya Zhao1,2, Mingxiang Feng3, Dong Liu1, Haixia Liu2, Mengmeng Shi1, Jing Zhang4, Jieming Qu5,2.   

Abstract

High temperature requirement A3 (HTRA3, long and short isoforms) is a member of the HtrA family and has been implicated as a tumor suppressor in cancer progression in multiple cancer types, yet its molecular functions in non-small cell lung cancer (NSCLC) are not well understood. Here, we report that decreased levels of HTRA3 negatively correlate with elevated TGFβ1 in lung tumor tissue with metastasis. Furthermore, high expression of HTRA3 indicated better prognosis independent of TGFβ1 expression. In NSCLC cell lines, exogenous TGFβ1 significantly downregulated the level of HTRA3, especially the long isoform, during induction of epithelial-mesenchymal transition (EMT). Mechanistically, c-Jun, which is elevated by TGFβ1, directly bound the promoter of HTRA3-L and inhibited its transcription. As a negative feedback loop, overexpression of HTRA3-L attenuated TGFβ1-mediated invasion-metastasis cascades via activation of SMAD2/3 and sensitized cells to anti-PD-L1 treatment. Taken together, our findings suggest that in the early stages of cancer, overexpressed HTRA3 acts as a brake on the oncogenic effects of TGFβ1 and inhibits tumor metastasis. In later stages, the role of HTRA3 is weakened and TGFβ1 efficiently promotes EMT in the absence of the HTRA3 brake. SIGNIFICANCE: This study provides new mechanistic insight of the interaction between HTRA3 and TGFβ in lung cancer by illustrating that HTRA3 is a novel mediator acting as a suppressor of TGFβ1-related oncogenic effects. ©2019 American Association for Cancer Research.

Entities:  

Year:  2019        PMID: 30940659     DOI: 10.1158/0008-5472.CAN-18-2507

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  5 in total

1.  A Novel Quantification System Combining iTRAQ Technology and Multi-Omics Assessment to Predict Prognosis and Immunotherapy Efficacy in Colon Cancer.

Authors:  Tianyi Xia; Junnan Guo; Bomiao Zhang; Weinan Xue; Shenhui Deng; Yanlong Liu; Binbin Cui
Journal:  Front Bioeng Biotechnol       Date:  2022-04-04

2.  Tumor Suppressors-HTRA Proteases and Interleukin-12-in Pediatric Asthma and Allergic Rhinitis Patients.

Authors:  Joanna Renke; Eliza Wasilewska; Sabina Kędzierska-Mieszkowska; Katarzyna Zorena; Sylwia Barańska; Tomasz Wenta; Anna Liberek; Danuta Siluk; Dorota Żurawa-Janicka; Aleksandra Szczepankiewicz; Marcin Renke; Barbara Lipińska
Journal:  Medicina (Kaunas)       Date:  2020-06-17       Impact factor: 2.430

3.  MIR22HG acts as a tumor suppressor via TGFβ/SMAD signaling and facilitates immunotherapy in colorectal cancer.

Authors:  Juan Xu; Tingting Shao; Mingxu Song; Yunjin Xie; Jialiang Zhou; Jiaqi Yin; Na Ding; Haozhe Zou; Yongsheng Li; Jiwei Zhang
Journal:  Mol Cancer       Date:  2020-03-04       Impact factor: 27.401

4.  Multi-omics analysis reveals prognostic value of tumor mutation burden in hepatocellular carcinoma.

Authors:  Qianhui Xu; Hao Xu; Rongshan Deng; Zijie Wang; Nanjun Li; Zhixuan Qi; Jiaxin Zhao; Wen Huang
Journal:  Cancer Cell Int       Date:  2021-07-03       Impact factor: 5.722

5.  PTBP3 mediates TGF-β-induced EMT and metastasis of lung adenocarcinoma.

Authors:  Chenglai Dong; Kaiqin Wu; Shaorui Gu; Wenli Wang; Shiliang Xie; Yongxin Zhou
Journal:  Cell Cycle       Date:  2022-03-24       Impact factor: 5.173

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.